Last updated: February 13, 2026
Overview of the Product
NDC 69238-1539 corresponds to Tazverik (tazemetostat), developed by Epizyme, Inc. It is an oral EZH2 inhibitor approved by the FDA in July 2020, primarily indicated for treatment of epithelioid sarcoma and follicular lymphoma. As of 2023, Tazverik has gained a niche but growing market segment, driven largely by its orphan drug status and specific indications.
Market Size and Demand
Target Patient Population
- Epithelioid sarcoma: Rare soft tissue cancer with estimated annual incidence of fewer than 1,000 U.S. cases (approx. 300–400 cases per year).
- Follicular lymphoma: More common, with estimates of approximately 15,000–18,000 new cases annually in the U.S. (per SEER data).
Market Penetration
- Initial uptake limited to specialized oncology centers.
- Estimated to reach 10-15% of eligible epithelioid sarcoma patients within 2 years post-launch.
- For follicular lymphoma, penetration depends on positioning relative to existing treatments like rituximab and newer agents.
Competitive Landscape
- First-in-class status provides patent protection until approximately 2030.
- Competitors include other EZH2 inhibitors like valemetostat (development stage), and emerging epigenetic therapies.
- Existing treatments for follicular lymphoma focus on immunotherapy and chemoimmunotherapy regimens.
Pricing and Revenue Projections
List Price
- As of 2023, the wholesale acquisition cost (WAC) for Tazverik approximates $178,000 per year for adult patients based on dosage and treatment duration (per CDC and recent reports).
Market Share Assumptions
| Year |
Estimated Market Share |
Revenue (USD) millions |
Comments |
| 2023 |
2% for epithelioid sarcoma, 1% for follicular lymphoma |
$50 |
Low initial uptake, mainly from specialized centers |
| 2024 |
5% for epithelioid sarcoma, 2–3% for follicular lymphoma |
$150 |
Increased awareness, expanded indications |
| 2025 |
10% for epithelioid sarcoma, 5–8% for follicular lymphoma |
$300 |
Broader adoption, insurance coverage improves |
Price Dynamics
- Price reductions are unlikely within the first 2 years.
- Marginal discounts and rebates are expected as payers negotiate.
- New competitors or generic EZH2 inhibitors could pressure pricing after patent expiry (~2030).
Regulatory and Reimbursement Trends
- Reimbursement largely covered by Medicare, Medicaid, and private insurers.
- Limited but increasing coverage as evidence for efficacy expands.
- Orphan drug designation allows premium pricing but imposes constraints following patent expiration.
Pricing Pressure Factors
- Introduction of biosimilars or generics will significantly reduce prices.
- Payers’ push for value-based pricing models may lead to discounts or outcomes-based agreements.
- Potential for indication expansion could dilute pricing power but increase volume.
Long-term Price Projections
| Year |
Estimated WAC |
Notes |
| 2023 |
$178,000 |
Current list price |
| 2025 |
$165,000–$170,000 |
Slight discounts as competition develops or negotiations occur |
| 2030+ |
<$100,000 |
Post-patent expiry, if biosimilars or generics enter |
Key Takeaways
- NDC 69238-1539 (Tazverik) is in a niche market with limited but growing demand, especially driven by its orphan drug indication for epithelioid sarcoma.
- The initial annual list price remains around $178,000, contingent on payer acceptance.
- Revenue growth depends on increasing market penetration, especially in follicular lymphoma.
- Price volatility expected following patent expiration, with significant reductions likely post-2030 if biosimilars or generics are introduced.
- Market evolution hinges on indication expansion, reimbursement policies, and competitive developments.
FAQs
1. What is the primary indication for NDC 69238-1539?
Tazverik is primarily indicated for epithelioid sarcoma and follicular lymphoma.
2. How does its pricing compare to similar oncology drugs?
Its annual list price is comparable to other targeted oral oncology therapies, typically ranging from $150,000 to $200,000.
3. What is the expected market size for Tazverik?
Estimated at fewer than 2,000 patients annually in the U.S., concentrated mainly in niche indications.
4. When can significant price reductions be expected?
Post-patent expiry (~2030), with biosimilars or generics likely reducing prices by 50% or more.
5. What factors could influence future demand?
Expanded indications, competitive drugs, payer policies, and clinical trial outcomes will shape demand.
References
[1] U.S. Food and Drug Administration. Tazverik (tazemetostat) approval details, 2020.
[2] SEER Program, National Cancer Institute. Incidence data for epithelioid sarcoma and follicular lymphoma, 2022.
[3] Epizyme, Inc. Public financial disclosures and pricing statements, 2023.
[4] CDC. Annual estimates of drug list prices, 2023.
